Compare Advance Auto Parts, Inc. (AAP) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advance Auto Parts, Inc. vs GSK plc — how do they compare? Advance Auto Parts, Inc. trades at $54.95 (market cap $3.37B), while GSK plc trades at $52.82 (market cap $105.91B). The key difference: GSK plc is far larger — about 31.4× Advance Auto Parts, Inc.'s market cap, and GSK plc pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| AAP | GSK | |
|---|---|---|
Market Cap | $3.37B | $105.91B |
Sector | Consumer Cyclical | Health |
52-Week High | $66.50 | $61.18 |
52-Week Low | $38.75 | $36.20 |
Enterprise Value | $5.64B | $126.53B |
Dividend Yield | 1.79% | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.86, down 9.22% today, reflecting recent pressure despite beating earnings estimates in three consecutive quarters. The stock shows a bearish technical signal with key support at $55 and resistance at $59. Fundamentally, revenue has declined from $11.2B in 2022 to $8.6B in 2025, though net income turned positive at $44M in 2025 after a loss in 2024. Recent news highlights a brand campaign and expanded delivery partnership with OneRail.
The outlook is mixed; analyst consensus is a Hold with a $60.89 price target, suggesting modest upside. Opportunities include margin expansion and turnaround progress, but risks involve competitive pressures, volatile cash flows, and high P/E ratio. Investor sentiment is cautious amid declining revenue trends.
GSK trades at $53.32, down 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $1.24 EPS, and maintains robust profitability with a 17.78% net income margin. Recent FDA approval for Utebzi and the $10.6 billion acquisition of Nuvalent highlight strategic expansion in oncology and anti-infectives.
Outlook remains positive with 7-9% EPS growth guidance for 2026, though risks include integration of large acquisitions and patent cliffs. Analyst consensus is mixed with 31% buy ratings, but solid fundamentals and recent approvals support a constructive view for long-term investors amid sector competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
